USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Sts Duotex Inc.
Address:
7500 West Henrietta Road
Rush, NY 14543
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $242,560.00 5
SBIR Phase II $1,000,000.00 2

Award List:

INSOLUBLE ANTINEOPLASTICS. PARTICLES FOR IV INJECTION

Award Year / Program / Phase:
1984 / SBIR / Phase I
Award Amount:
$43,356.00
Agency:
HHS
Principal Investigator:
Michael R. Violante , Vice President
Abstract:
N/a

INSOLUBLE ANTINEOPLASTICS. PARTICLES FOR IV INJECTION

Award Year / Program / Phase:
1986 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Michael R. Violante , Vice President
Abstract:
Numerous compounds with known or suspected antineoplastic activity have been synthesized, which frequently are too insoluble or unstable in aqueous media for parenteral administration. some of these compounds are not sufficiently soluble even with ph adjustment or minor solvent reformulations, and… More

CONTROL AND STANDARDIZATION OF APOLIPOPROTEIN ASSAYS

Award Year / Program / Phase:
1988 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
In 1984 an nih consensus conference recommended community based cholesterol screening programs to evaluate hypercholesterolemia in the context of its association with increased heart attacks. there is a developing literature that the apolipoproteins a-1 and b are better measures of risk than hdl and… More

DEVELOPMENT OF AN ANTIMICROBIAL URETHRAL URINARY CATHETER FOR LONG-TERM INDWELLING URETHRAL CATHETERIZATION

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Richard Whitbourne
Abstract:
This project will further develop two methods for incorporating antibiotics into surface coatings and will also compare the relative utility of the two methods, directincorporation of the antibiotic into the coating at manufacture vs. imbibition of the antibiotic into the coating just prior to… More

IMPROVED INHALATION THERAPY OF AIDS-RELATED INFECTIONS

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,904.00
Agency:
HHS
Principal Investigator:
Violante, Michael R , Principal Investigator
Abstract:
The majority of aids patients, when first examined, have symptoms of opportunistic infections, the most common being pneumocystis carinii. the high mortality rate defines a need for treatment and prophylaxis of this and other life- threatening opportunistic infections. pentamidine has a role to… More

IMPROVED BINDING OF ANTITHROMBOGENIC AGENTS TO POLYMERS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$49,300.00
Agency:
HHS
Principal Investigator:
Richard J Whitbourne
Abstract:
N/a

IMPROVED BINDING OF ANTITHROMBOGENIC AGENTS TO POLYMERS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Richard J Whitbourne
Abstract:
We will develop and evaluate polymer coatings containing anticoagulant drugs. these polymers, when applied to the surface of a prosthesis that comes in contact with blood, renders the device nonthrombogenic. thus frequently encountered clinical complications related to thrombus formation are… More